Case report

Parotid metastasis from renal cell carcinoma: a case report and review of the literature

Metastasi parotide da carcinoma a cellule renali: caso clinico e revisione della letteratura

R. SPREAFICO, G. NICOLETTI, F. FERRARIO, R. SCANZIANI, M. GRASSO
Otorhinolaryngology Unit; Nephrology Unit; Urology Unit, Desio Hospital, Desio (Milan), Italy

Summary

Renal cell carcinoma metastasis to the parotid gland after tumour nephrectomy is extremely rare. Herewith a review of the literature on this topic is discussed and a case report is presented of a 69-year-old man affected by parotid localization of renal clear cell carcinoma with neck lymph node metastases and involvement of the masseter muscle 2 years after nephrectomy. When an otolaryngologist encounters a parotid mass, diverse differential diagnoses have to be considered. A high level of suspicion of metastatic disease from the specific primary site will help in achieving correct diagnosis and evaluation of the extension of the disease. Surgical resection, even enlarged parotidectomy with neck dissection, should be considered as a therapeutic option for exclusive location of the disease in the head and neck.

Key Words: Parotid • Malignant tumours • Metastasis • Renal cell carcinoma • Therapy

Case-report

In May 2005, a 67-year-old man underwent right nephrectomy for renal clear cell carcinoma (pT2N0, G2). During his adolescence, the patient had been affected by tubercular pleuritis. In 1998, moderate chronic renal failure was diagnosed. After right nephrectomy, renal failure rapidly worsened requiring dialysis with subsequent clinical improvement. For the remainder of 2005, the patient was free of disease until November 2006 when physicians discovered a deeply adherent, painless mass in the right parotid region. On clinical examination, there was no facial weakness. Fine needle aspiration biopsy (FNAB) was immediately performed and the pathologist’s report showed metastasis from renal cell carcinoma. On a computed tomography (CT) scan with contrast of the head and neck, a large bulge of the right parotid gland involving the masseter muscle and two suspicious ipsilateral neck lymphadenopathies were visible (Figs. 1, 2).

Metastatic work-up, by total-body 6FDG-PET, was com-

Fig. 1. Computed tomography scan revealing enhancing mass in parotid gland with extension to masseter muscle.
Parotid metastasis from renal cell carcinoma

The pathological specimen showed a 6 x 4 cm parotid tumour and 3 x 3 cm neck lymph nodes. On histological and immunohistochemical examination, patterns of renal clear cell carcinoma, diffusely infiltrating, and the presence of two massive neck lymph node metastases were confirmed (Fig. 5). Negative surgical margins were obtained. The treatment was completed by radiotherapy.

Discussion

Metastasis to the parotid gland rarely occurs and usually proceeds from skin cancers of the head and neck, such as melanoma in 45% of cases and squamous cell carcinoma in 37%. Melanoma is more frequently observed in paraparotid lymph nodes (70%) while squamous cell carcinoma of the skin involves the intraglandular lymph nodes (47%). When the primary cancer originates in sites below the clavicle, metastases to the head and neck are uncommon. Parotid localization from renal cell carcinoma is an extremely rare finding. In a large series of patients with renal cell carcinoma, with metastases to the head and neck, parotid metastases never occurred.

The mechanism by which a renal cell carcinoma reaches the parotid gland is probably the haematogeneous spread. In fact, renal cell carcinomas are hypervascular tumours associated with multiple arteriovenous shunt. Considering the fact that kidneys receive 25% of circulating blood volume, renal cell carcinoma has a high haematogeneous spreading potential. In order of frequency, renal cell carcinoma commonly metastatizes to lung, bone, liver, brain and skin, while metastases to the head and neck region are rarer (8-14%), the thyroid accounting for a large percentage of cases.

The English language literature identifies 26 cases of renal cell carcinoma, metastatic to the parotid gland, while taking into account that most patients presented multiple metastases and solitary parotid location is extremely rare. In 14 of these patients, parotid metastasis was the initial sign of malignancy in the kidney. On the other hand, in 12 patients, parotid metastasis occurred after the primary treatment for renal cell carcinoma, at a time interval ranging from months to years. To our knowledge, the longest interval from nephrectomy to solitary parotid metastasis is 10 years, with only one case reported in the literature.
In patients presenting with parotid bulk, unless one maintains a high index of suspicion, the unsuspected disease may be completely overlooked. Radiological findings are indistinguishable from those of a primary cancer. Parotid ultrasonography reveals a heterogeneous lesion and head and neck CT with contrast findings are not specific.

As in our case, some Authors confirm the diagnosis using FNAB although false-positive and false-negative cases have been reported. Even when FNAB cannot differentiate between primary parotid cancer and metastases from other primary lesions, it provides important information for management of the patient.

In recent years, new diagnostic techniques have provided the possibility to evaluate the metabolism of several lesions by the uptake of radioactive glucose. If carcinoma is identified on parotid FNAB in a patient with a history of renal cell carcinoma, re-staging with 6FDG-PET is mandatory. In our case, data of previous nephrectomy and actual renal cell carcinoma metastasis were strongly suspicious because of neoplastic emboli spreading in multiple sites.

On the basis of the extension of the disease, treatment is consistently different. Treatment of diffuse metastatic disease is a combination of chemotherapy, immunotherapy, hormone therapy and radiation therapy, but the results are dismal. On the other hand, it is well known that management for clinically solitary metastasis is aggressive surgical resection. In patients with a solitary metastasis amenable to surgical resection the five-year survival rate was 53%.

Solitary parotid metastasis and a long interval are favourable prognostic factors. If the parotid gland is the only site affected, the patient should undergo superficial parotidectomy with preservation of the facial nerve. Taking into account our experience and our review of the literature, when parotid metastasis extends to the surrounding anatomical structures, their surgical resection is, in our opinion, a correct approach to cure the patient. In the case described hereewith, parotidectomy was enlarged to the deep lobe, the masseter muscle, the inferior branch of the facial nerve and selective (level I-V) neck dissection was performed.

The involvement of structures, like muscle and nerve, that give the cancer cells a theoretical way of spreading and two massive metastases present in the lymph nodes in the neck, argued in favour of performing radiotherapy.

In conclusion, we want to emphasize the following items:

- when parotid bulk appears, the history of the patient should be checked carefully;
- FNAB is of major importance in orientating the diagnosis;
- 6FDG-PET contributes greatly to cancer re-staging;
- surgery, even with resection wider than superficial parotidectomy, possibly associated with post-operative radiotherapy, should be considered as a therapeutic option when metastatic disease affects the parotid gland, its surrounding structures and the lymph nodes, on that side of the neck, but is not present in other parts of the body.

References